Listed in the December 27, 2023 extract; not in the current extract (Aug 26, 2026): Nat-Citalopram (02409011), Nat-Citalopram (02409038). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-08-26.xml.
CITALOPRAM HYDROBROMIDE
16 general benefit · 8 not a benefit
Other products in the same Health Canada class (N06A, N06AB) — coverage varies; not interchangeable
- Escitalopram (Cipralex MELTZ): general benefit, Not a benefit
- Fluoxetine (Prozac): general benefit, Not a benefit
- Fluvoxamine (Luvox): general benefit
- Paroxetine (Paxil): general benefit, Not a benefit
- Sertraline (Zoloft): general benefit
- Amitriptyline (Elavil): general benefit
17 more in the class list below
Apo-Citalopram · DIN 02246056 · 20mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Citalopram · DIN 02246056
Manufacturer: Apotex Inc.; listing date 2004-07-20
Health Canada: Marketed since 2004-01-21 · brand APO-CITALOPRAM · ATC N06AB04 CITALOPRAM · form Tablet · route Oral · ingredients CITALOPRAM (CITALOPRAM HYDROBROMIDE) 20 MG · company Apotex inc · schedule Prescription
Apo-Citalopram: Formulary list price $0.1332/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1332 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=70187 · Verify on the e-Formulary ↗ (DIN 02246056)
Source record
DIN 02246056: Apo-Citalopram
Raw flags: sec3=Y
Item: 281604096; group id 454; item number 1133; lccId None; manufacturer id APX
Source form: Tab; strength: 20mg
Recorded listing: General benefit
Source prices (unrounded): $0.1332; ministry $0.1332
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02246056
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=70187
Interchangeable products
Accel Citalopram Tablets · DIN 02355256 · $0.1332
Auro-Citalopram · DIN 02275562 · $0.1332
CCP-Citalopram · DIN 02459914 · $0.1332
Celexa · DIN 02239607 · $0.1332
Citalopram · DIN 02353660 · $0.1332
Citalopram · DIN 02387956 · $0.1332
Citalopram · DIN 02430541 · $0.1332
Co Citalopram · DIN 02248050 · $0.1332
Jamp-Citalopram · DIN 02313405 · $0.1332
M-Citalopram · DIN 02467836 · $0.1332
Mar-Citalopram · DIN 02371898 · $0.1332
Mint-Citalopram · DIN 02429705 · $0.1332
NRA-Citalopram · DIN 02477645 · $0.1332
Natco-Citalopram · DIN 02443880 · $0.1332
PMS-Citalopram · DIN 02248010 · $0.1332
Ran-Citalo · DIN 02285622 · $0.1332
Riva-Citalopram · DIN 02303264 · $0.1332
Sandoz Citalopram · DIN 02248170 · $0.1332
Septa-Citalopram · DIN 02355272 · $0.1332
Teva-Citalopram · DIN 02293218 · $0.1332
Shortage status: resolved shortage (ended 2024-10-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02246056
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Auro-Citalopram · DIN 02275562 · 20mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Citalopram · DIN 02275562
Manufacturer: Auro Pharma Inc.; listing date 2012-03-26
Health Canada: Marketed since 2011-11-28 · brand AURO-CITALOPRAM · ATC N06AB04 CITALOPRAM · form Tablet · route Oral · ingredients CITALOPRAM (CITALOPRAM HYDROBROMIDE) 20 MG · company Auro pharma inc · schedule Prescription
Auro-Citalopram: Formulary list price $0.1332/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1332 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76120 · Verify on the e-Formulary ↗ (DIN 02275562)
Source record
DIN 02275562: Auro-Citalopram
Raw flags: sec3=Y
Item: 281604096; group id 454; item number 1133; lccId None; manufacturer id AUR
Source form: Tab; strength: 20mg
Recorded listing: General benefit
Source prices (unrounded): $0.1332; ministry $0.1332
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02275562
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76120
Interchangeable products
Accel Citalopram Tablets · DIN 02355256 · $0.1332
Apo-Citalopram · DIN 02246056 · $0.1332
CCP-Citalopram · DIN 02459914 · $0.1332
Celexa · DIN 02239607 · $0.1332
Citalopram · DIN 02353660 · $0.1332
Citalopram · DIN 02387956 · $0.1332
Citalopram · DIN 02430541 · $0.1332
Co Citalopram · DIN 02248050 · $0.1332
Jamp-Citalopram · DIN 02313405 · $0.1332
M-Citalopram · DIN 02467836 · $0.1332
Mar-Citalopram · DIN 02371898 · $0.1332
Mint-Citalopram · DIN 02429705 · $0.1332
NRA-Citalopram · DIN 02477645 · $0.1332
Natco-Citalopram · DIN 02443880 · $0.1332
PMS-Citalopram · DIN 02248010 · $0.1332
Ran-Citalo · DIN 02285622 · $0.1332
Riva-Citalopram · DIN 02303264 · $0.1332
Sandoz Citalopram · DIN 02248170 · $0.1332
Septa-Citalopram · DIN 02355272 · $0.1332
Teva-Citalopram · DIN 02293218 · $0.1332
Shortage status: resolved shortage (ended 2021-08-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02275562
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Celexa · DIN 02239607 · 20mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: innoviCares lists Celexa (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up.
(innovicares.ca ↗)1 brand, same coverage
Celexa · DIN 02239607
Manufacturer: Lundbeck Canada Inc.; listing date 2000-01-17
Health Canada: Marketed since 1999-03-08 · brand CELEXA 20 MG · ATC N06AB04 CITALOPRAM · form Tablet · route Oral · ingredients CITALOPRAM (CITALOPRAM HYDROBROMIDE) 20 MG · company Lundbeck canada inc · schedule Prescription
Ministry pays: $0.1332 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63077 · Verify on the e-Formulary ↗ (DIN 02239607)
Source record
DIN 02239607: Celexa
Raw flags: sec3=Y
Item: 281604096; group id 454; item number 1133; lccId None; manufacturer id VLH
Source form: Tab; strength: 20mg
Recorded listing: General benefit
Source prices (unrounded): $1.8776; ministry $0.1332
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02239607
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63077
Interchangeable products
Accel Citalopram Tablets · DIN 02355256 · $0.1332
Apo-Citalopram · DIN 02246056 · $0.1332
Auro-Citalopram · DIN 02275562 · $0.1332
CCP-Citalopram · DIN 02459914 · $0.1332
Citalopram · DIN 02353660 · $0.1332
Citalopram · DIN 02387956 · $0.1332
Citalopram · DIN 02430541 · $0.1332
Co Citalopram · DIN 02248050 · $0.1332
Jamp-Citalopram · DIN 02313405 · $0.1332
M-Citalopram · DIN 02467836 · $0.1332
Mar-Citalopram · DIN 02371898 · $0.1332
Mint-Citalopram · DIN 02429705 · $0.1332
NRA-Citalopram · DIN 02477645 · $0.1332
Natco-Citalopram · DIN 02443880 · $0.1332
PMS-Citalopram · DIN 02248010 · $0.1332
Ran-Citalo · DIN 02285622 · $0.1332
Riva-Citalopram · DIN 02303264 · $0.1332
Sandoz Citalopram · DIN 02248170 · $0.1332
Septa-Citalopram · DIN 02355272 · $0.1332
Teva-Citalopram · DIN 02293218 · $0.1332
Shortage status: resolved shortage (ended 2020-08-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02239607
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Citalopram · DIN 02353660 · 20mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Citalopram · DIN 02353660
Manufacturer: Sanis Health Inc.; listing date 2011-08-04
Health Canada: Marketed since 2016-01-06 · brand CITALOPRAM · ATC N06AB04 CITALOPRAM · form Tablet · route Oral · ingredients CITALOPRAM (CITALOPRAM HYDROBROMIDE) 20 MG · company Sanis health inc · schedule Prescription
Citalopram: Formulary list price $0.1332/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1332 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83886 · Verify on the e-Formulary ↗ (DIN 02353660)
Source record
DIN 02353660: Citalopram
Raw flags: sec3=Y
Item: 281604096; group id 454; item number 1133; lccId None; manufacturer id SAI
Source form: Tab; strength: 20mg
Recorded listing: General benefit
Source prices (unrounded): $0.1332; ministry $0.1332
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02353660
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83886
Interchangeable products
Accel Citalopram Tablets · DIN 02355256 · $0.1332
Apo-Citalopram · DIN 02246056 · $0.1332
Auro-Citalopram · DIN 02275562 · $0.1332
CCP-Citalopram · DIN 02459914 · $0.1332
Celexa · DIN 02239607 · $0.1332
Citalopram · DIN 02387956 · $0.1332
Citalopram · DIN 02430541 · $0.1332
Co Citalopram · DIN 02248050 · $0.1332
Jamp-Citalopram · DIN 02313405 · $0.1332
M-Citalopram · DIN 02467836 · $0.1332
Mar-Citalopram · DIN 02371898 · $0.1332
Mint-Citalopram · DIN 02429705 · $0.1332
NRA-Citalopram · DIN 02477645 · $0.1332
Natco-Citalopram · DIN 02443880 · $0.1332
PMS-Citalopram · DIN 02248010 · $0.1332
Ran-Citalo · DIN 02285622 · $0.1332
Riva-Citalopram · DIN 02303264 · $0.1332
Sandoz Citalopram · DIN 02248170 · $0.1332
Septa-Citalopram · DIN 02355272 · $0.1332
Teva-Citalopram · DIN 02293218 · $0.1332
Shortage status: resolved shortage (ended 2020-10-29); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02353660
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Citalopram · DIN 02387956 · 20mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Citalopram · DIN 02387956
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-11-30
Health Canada: Marketed since 2024-02-27 · brand CITALOPRAM · ATC N06AB04 CITALOPRAM · form Tablet · route Oral · ingredients CITALOPRAM (CITALOPRAM HYDROBROMIDE) 20 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Citalopram: Formulary list price $0.1332/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1332 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87352 · Verify on the e-Formulary ↗ (DIN 02387956)
Source record
DIN 02387956: Citalopram
Raw flags: sec3=Y
Item: 281604096; group id 454; item number 1133; lccId None; manufacturer id SIV
Source form: Tab; strength: 20mg
Recorded listing: General benefit
Source prices (unrounded): $0.1332; ministry $0.1332
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02387956
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87352
Interchangeable products
Accel Citalopram Tablets · DIN 02355256 · $0.1332
Apo-Citalopram · DIN 02246056 · $0.1332
Auro-Citalopram · DIN 02275562 · $0.1332
CCP-Citalopram · DIN 02459914 · $0.1332
Celexa · DIN 02239607 · $0.1332
Citalopram · DIN 02353660 · $0.1332
Citalopram · DIN 02430541 · $0.1332
Co Citalopram · DIN 02248050 · $0.1332
Jamp-Citalopram · DIN 02313405 · $0.1332
M-Citalopram · DIN 02467836 · $0.1332
Mar-Citalopram · DIN 02371898 · $0.1332
Mint-Citalopram · DIN 02429705 · $0.1332
NRA-Citalopram · DIN 02477645 · $0.1332
Natco-Citalopram · DIN 02443880 · $0.1332
PMS-Citalopram · DIN 02248010 · $0.1332
Ran-Citalo · DIN 02285622 · $0.1332
Riva-Citalopram · DIN 02303264 · $0.1332
Sandoz Citalopram · DIN 02248170 · $0.1332
Septa-Citalopram · DIN 02355272 · $0.1332
Teva-Citalopram · DIN 02293218 · $0.1332
Shortage status: resolved shortage (ended 2021-10-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02387956
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Citalopram · DIN 02430541 · 20mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Citalopram · DIN 02430541
Manufacturer: Jamp Pharma Corporation; listing date 2015-01-28
Health Canada: Marketed since 2020-03-06 · brand CITALOPRAM · ATC N06AB04 CITALOPRAM · form Tablet · route Oral · ingredients CITALOPRAM (CITALOPRAM HYDROBROMIDE) 20 MG · company Jamp pharma corporation · schedule Prescription
Citalopram: Formulary list price $0.1332/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1332 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91496 · Verify on the e-Formulary ↗ (DIN 02430541)
Source record
DIN 02430541: Citalopram
Raw flags: sec3=Y
Item: 281604096; group id 454; item number 1133; lccId None; manufacturer id JPC
Source form: Tab; strength: 20mg
Recorded listing: General benefit
Source prices (unrounded): $0.1332; ministry $0.1332
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02430541
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91496
Interchangeable products
Accel Citalopram Tablets · DIN 02355256 · $0.1332
Apo-Citalopram · DIN 02246056 · $0.1332
Auro-Citalopram · DIN 02275562 · $0.1332
CCP-Citalopram · DIN 02459914 · $0.1332
Celexa · DIN 02239607 · $0.1332
Citalopram · DIN 02353660 · $0.1332
Citalopram · DIN 02387956 · $0.1332
Co Citalopram · DIN 02248050 · $0.1332
Jamp-Citalopram · DIN 02313405 · $0.1332
M-Citalopram · DIN 02467836 · $0.1332
Mar-Citalopram · DIN 02371898 · $0.1332
Mint-Citalopram · DIN 02429705 · $0.1332
NRA-Citalopram · DIN 02477645 · $0.1332
Natco-Citalopram · DIN 02443880 · $0.1332
PMS-Citalopram · DIN 02248010 · $0.1332
Ran-Citalo · DIN 02285622 · $0.1332
Riva-Citalopram · DIN 02303264 · $0.1332
Sandoz Citalopram · DIN 02248170 · $0.1332
Septa-Citalopram · DIN 02355272 · $0.1332
Teva-Citalopram · DIN 02293218 · $0.1332
Shortage status: resolved shortage (ended 2025-12-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02430541
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp-Citalopram · DIN 02313405 · 20mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp-Citalopram · DIN 02313405
Manufacturer: Jamp Pharma Corporation; listing date 2009-01-30
Health Canada: Marketed since 2025-08-15 · brand JAMP-CITALOPRAM · ATC N06AB04 CITALOPRAM · form Tablet · route Oral · ingredients CITALOPRAM (CITALOPRAM HYDROBROMIDE) 20 MG · company Jamp pharma corporation · schedule Prescription
Jamp-Citalopram: Formulary list price $0.1332/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1332 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79893 · Verify on the e-Formulary ↗ (DIN 02313405)
Source record
DIN 02313405: Jamp-Citalopram
Raw flags: sec3=Y
Item: 281604096; group id 454; item number 1133; lccId None; manufacturer id JPC
Source form: Tab; strength: 20mg
Recorded listing: General benefit
Source prices (unrounded): $0.1332; ministry $0.1332
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02313405
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79893
Interchangeable products
Accel Citalopram Tablets · DIN 02355256 · $0.1332
Apo-Citalopram · DIN 02246056 · $0.1332
Auro-Citalopram · DIN 02275562 · $0.1332
CCP-Citalopram · DIN 02459914 · $0.1332
Celexa · DIN 02239607 · $0.1332
Citalopram · DIN 02353660 · $0.1332
Citalopram · DIN 02387956 · $0.1332
Citalopram · DIN 02430541 · $0.1332
Co Citalopram · DIN 02248050 · $0.1332
M-Citalopram · DIN 02467836 · $0.1332
Mar-Citalopram · DIN 02371898 · $0.1332
Mint-Citalopram · DIN 02429705 · $0.1332
NRA-Citalopram · DIN 02477645 · $0.1332
Natco-Citalopram · DIN 02443880 · $0.1332
PMS-Citalopram · DIN 02248010 · $0.1332
Ran-Citalo · DIN 02285622 · $0.1332
Riva-Citalopram · DIN 02303264 · $0.1332
Sandoz Citalopram · DIN 02248170 · $0.1332
Septa-Citalopram · DIN 02355272 · $0.1332
Teva-Citalopram · DIN 02293218 · $0.1332
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02313405
Shortage record checked 2026-09-13T08:10:21.292534+00:00
M-Citalopram · DIN 02467836 · 20mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
M-Citalopram · DIN 02467836
Manufacturer: Mantra Pharma Inc.; listing date 2023-12-29
Health Canada: Marketed since 2023-11-13 · brand M-CITALOPRAM · ATC N06AB04 CITALOPRAM · form Tablet · route Oral · ingredients CITALOPRAM (CITALOPRAM HYDROBROMIDE) 20 MG · company Mantra pharma inc · schedule Prescription
M-Citalopram: Formulary list price $0.1332/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1332 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95617 · Verify on the e-Formulary ↗ (DIN 02467836)
Source record
DIN 02467836: M-Citalopram
Raw flags: sec3=Y
Item: 281604096; group id 454; item number 1133; lccId None; manufacturer id MAT
Source form: Tab; strength: 20mg
Recorded listing: General benefit
Source prices (unrounded): $0.1332; ministry $0.1332
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02467836
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95617
Interchangeable products
Accel Citalopram Tablets · DIN 02355256 · $0.1332
Apo-Citalopram · DIN 02246056 · $0.1332
Auro-Citalopram · DIN 02275562 · $0.1332
CCP-Citalopram · DIN 02459914 · $0.1332
Celexa · DIN 02239607 · $0.1332
Citalopram · DIN 02353660 · $0.1332
Citalopram · DIN 02387956 · $0.1332
Citalopram · DIN 02430541 · $0.1332
Co Citalopram · DIN 02248050 · $0.1332
Jamp-Citalopram · DIN 02313405 · $0.1332
Mar-Citalopram · DIN 02371898 · $0.1332
Mint-Citalopram · DIN 02429705 · $0.1332
NRA-Citalopram · DIN 02477645 · $0.1332
Natco-Citalopram · DIN 02443880 · $0.1332
PMS-Citalopram · DIN 02248010 · $0.1332
Ran-Citalo · DIN 02285622 · $0.1332
Riva-Citalopram · DIN 02303264 · $0.1332
Sandoz Citalopram · DIN 02248170 · $0.1332
Septa-Citalopram · DIN 02355272 · $0.1332
Teva-Citalopram · DIN 02293218 · $0.1332
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02467836
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mar-Citalopram · DIN 02371898 · 20mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mar-Citalopram · DIN 02371898
Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2012-01-19
Health Canada: Marketed since 2012-09-06 · brand MAR-CITALOPRAM · ATC N06AB04 CITALOPRAM · form Tablet · route Oral · ingredients CITALOPRAM (CITALOPRAM HYDROBROMIDE) 20 MG · company Marcan pharmaceuticals inc · schedule Prescription
Mar-Citalopram: Formulary list price $0.1332/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1332 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85701 · Verify on the e-Formulary ↗ (DIN 02371898)
Source record
DIN 02371898: Mar-Citalopram
Raw flags: sec3=Y
Item: 281604096; group id 454; item number 1133; lccId None; manufacturer id MAR
Source form: Tab; strength: 20mg
Recorded listing: General benefit
Source prices (unrounded): $0.1332; ministry $0.1332
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02371898
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85701
Interchangeable products
Accel Citalopram Tablets · DIN 02355256 · $0.1332
Apo-Citalopram · DIN 02246056 · $0.1332
Auro-Citalopram · DIN 02275562 · $0.1332
CCP-Citalopram · DIN 02459914 · $0.1332
Celexa · DIN 02239607 · $0.1332
Citalopram · DIN 02353660 · $0.1332
Citalopram · DIN 02387956 · $0.1332
Citalopram · DIN 02430541 · $0.1332
Co Citalopram · DIN 02248050 · $0.1332
Jamp-Citalopram · DIN 02313405 · $0.1332
M-Citalopram · DIN 02467836 · $0.1332
Mint-Citalopram · DIN 02429705 · $0.1332
NRA-Citalopram · DIN 02477645 · $0.1332
Natco-Citalopram · DIN 02443880 · $0.1332
PMS-Citalopram · DIN 02248010 · $0.1332
Ran-Citalo · DIN 02285622 · $0.1332
Riva-Citalopram · DIN 02303264 · $0.1332
Sandoz Citalopram · DIN 02248170 · $0.1332
Septa-Citalopram · DIN 02355272 · $0.1332
Teva-Citalopram · DIN 02293218 · $0.1332
Shortage status: resolved shortage (ended 2018-09-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02371898
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mint-Citalopram · DIN 02429705 · 20mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mint-Citalopram · DIN 02429705
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2015-12-22
Health Canada: Marketed since 2015-10-14 · brand MINT-CITALOPRAM · ATC N06AB04 CITALOPRAM · form Tablet · route Oral · ingredients CITALOPRAM (CITALOPRAM HYDROBROMIDE) 20 MG · company Mint pharmaceuticals inc · schedule Prescription
Mint-Citalopram: Formulary list price $0.1332/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1332 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91415 · Verify on the e-Formulary ↗ (DIN 02429705)
Source record
DIN 02429705: Mint-Citalopram
Raw flags: sec3=Y
Item: 281604096; group id 454; item number 1133; lccId None; manufacturer id MIN
Source form: Tab; strength: 20mg
Recorded listing: General benefit
Source prices (unrounded): $0.1332; ministry $0.1332
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02429705
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91415
Interchangeable products
Accel Citalopram Tablets · DIN 02355256 · $0.1332
Apo-Citalopram · DIN 02246056 · $0.1332
Auro-Citalopram · DIN 02275562 · $0.1332
CCP-Citalopram · DIN 02459914 · $0.1332
Celexa · DIN 02239607 · $0.1332
Citalopram · DIN 02353660 · $0.1332
Citalopram · DIN 02387956 · $0.1332
Citalopram · DIN 02430541 · $0.1332
Co Citalopram · DIN 02248050 · $0.1332
Jamp-Citalopram · DIN 02313405 · $0.1332
M-Citalopram · DIN 02467836 · $0.1332
Mar-Citalopram · DIN 02371898 · $0.1332
NRA-Citalopram · DIN 02477645 · $0.1332
Natco-Citalopram · DIN 02443880 · $0.1332
PMS-Citalopram · DIN 02248010 · $0.1332
Ran-Citalo · DIN 02285622 · $0.1332
Riva-Citalopram · DIN 02303264 · $0.1332
Sandoz Citalopram · DIN 02248170 · $0.1332
Septa-Citalopram · DIN 02355272 · $0.1332
Teva-Citalopram · DIN 02293218 · $0.1332
Shortage status: resolved shortage (ended 2023-05-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02429705
Shortage record checked 2026-09-13T08:10:21.292534+00:00
NRA-Citalopram · DIN 02477645 · 20mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
NRA-Citalopram · DIN 02477645
Manufacturer: Nora Pharma; listing date 2023-01-31
Health Canada: Marketed since 2025-11-21 · brand NRA-CITALOPRAM · ATC N06AB04 CITALOPRAM · form Tablet · route Oral · ingredients CITALOPRAM (CITALOPRAM HYDROBROMIDE) 20 MG · company Nora pharma inc · schedule Prescription
NRA-Citalopram: Formulary list price $0.1332/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1332 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96829 · Verify on the e-Formulary ↗ (DIN 02477645)
Source record
DIN 02477645: NRA-Citalopram
Raw flags: sec3=Y
Item: 281604096; group id 454; item number 1133; lccId None; manufacturer id NRA
Source form: Tab; strength: 20mg
Recorded listing: General benefit
Source prices (unrounded): $0.1332; ministry $0.1332
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02477645
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96829
Interchangeable products
Accel Citalopram Tablets · DIN 02355256 · $0.1332
Apo-Citalopram · DIN 02246056 · $0.1332
Auro-Citalopram · DIN 02275562 · $0.1332
CCP-Citalopram · DIN 02459914 · $0.1332
Celexa · DIN 02239607 · $0.1332
Citalopram · DIN 02353660 · $0.1332
Citalopram · DIN 02387956 · $0.1332
Citalopram · DIN 02430541 · $0.1332
Co Citalopram · DIN 02248050 · $0.1332
Jamp-Citalopram · DIN 02313405 · $0.1332
M-Citalopram · DIN 02467836 · $0.1332
Mar-Citalopram · DIN 02371898 · $0.1332
Mint-Citalopram · DIN 02429705 · $0.1332
Natco-Citalopram · DIN 02443880 · $0.1332
PMS-Citalopram · DIN 02248010 · $0.1332
Ran-Citalo · DIN 02285622 · $0.1332
Riva-Citalopram · DIN 02303264 · $0.1332
Sandoz Citalopram · DIN 02248170 · $0.1332
Septa-Citalopram · DIN 02355272 · $0.1332
Teva-Citalopram · DIN 02293218 · $0.1332
Shortage status: active shortage (reported 2025-09-01, estimated to end 2026-09-30, last updated 2026-06-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02477645
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Natco-Citalopram · DIN 02443880 · 20mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Natco-Citalopram · DIN 02443880
Manufacturer: Natco Pharma (Canada) Inc.; listing date 2023-10-31
Health Canada: Marketed since 2023-09-18 · brand NATCO-CITALOPRAM · ATC N06AB04 CITALOPRAM · form Tablet · route Oral · ingredients CITALOPRAM (CITALOPRAM HYDROBROMIDE) 20 MG · company Natco pharma (canada) inc · schedule Prescription
Natco-Citalopram: Formulary list price $0.1332/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1332 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92865 · Verify on the e-Formulary ↗ (DIN 02443880)
Source record
DIN 02443880: Natco-Citalopram
Raw flags: sec3=Y
Item: 281604096; group id 454; item number 1133; lccId None; manufacturer id NAT
Source form: Tab; strength: 20mg
Recorded listing: General benefit
Source prices (unrounded): $0.1332; ministry $0.1332
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02443880
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92865
Interchangeable products
Accel Citalopram Tablets · DIN 02355256 · $0.1332
Apo-Citalopram · DIN 02246056 · $0.1332
Auro-Citalopram · DIN 02275562 · $0.1332
CCP-Citalopram · DIN 02459914 · $0.1332
Celexa · DIN 02239607 · $0.1332
Citalopram · DIN 02353660 · $0.1332
Citalopram · DIN 02387956 · $0.1332
Citalopram · DIN 02430541 · $0.1332
Co Citalopram · DIN 02248050 · $0.1332
Jamp-Citalopram · DIN 02313405 · $0.1332
M-Citalopram · DIN 02467836 · $0.1332
Mar-Citalopram · DIN 02371898 · $0.1332
Mint-Citalopram · DIN 02429705 · $0.1332
NRA-Citalopram · DIN 02477645 · $0.1332
PMS-Citalopram · DIN 02248010 · $0.1332
Ran-Citalo · DIN 02285622 · $0.1332
Riva-Citalopram · DIN 02303264 · $0.1332
Sandoz Citalopram · DIN 02248170 · $0.1332
Septa-Citalopram · DIN 02355272 · $0.1332
Teva-Citalopram · DIN 02293218 · $0.1332
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02443880
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PMS-Citalopram · DIN 02248010 · 20mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
PMS-Citalopram · DIN 02248010
Manufacturer: Pharmascience Inc.; listing date 2004-07-20
Health Canada: Marketed since 2004-01-15 · brand PMS-CITALOPRAM · ATC N06AB04 CITALOPRAM · form Tablet · route Oral · ingredients CITALOPRAM (CITALOPRAM HYDROBROMIDE) 20 MG · company Pharmascience inc · schedule Prescription
PMS-Citalopram: Formulary list price $0.1332/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1332 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72326 · Verify on the e-Formulary ↗ (DIN 02248010)
Source record
DIN 02248010: PMS-Citalopram
Raw flags: sec3=Y
Item: 281604096; group id 454; item number 1133; lccId None; manufacturer id PMS
Source form: Tab; strength: 20mg
Recorded listing: General benefit
Source prices (unrounded): $0.1332; ministry $0.1332
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02248010
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72326
Interchangeable products
Accel Citalopram Tablets · DIN 02355256 · $0.1332
Apo-Citalopram · DIN 02246056 · $0.1332
Auro-Citalopram · DIN 02275562 · $0.1332
CCP-Citalopram · DIN 02459914 · $0.1332
Celexa · DIN 02239607 · $0.1332
Citalopram · DIN 02353660 · $0.1332
Citalopram · DIN 02387956 · $0.1332
Citalopram · DIN 02430541 · $0.1332
Co Citalopram · DIN 02248050 · $0.1332
Jamp-Citalopram · DIN 02313405 · $0.1332
M-Citalopram · DIN 02467836 · $0.1332
Mar-Citalopram · DIN 02371898 · $0.1332
Mint-Citalopram · DIN 02429705 · $0.1332
NRA-Citalopram · DIN 02477645 · $0.1332
Natco-Citalopram · DIN 02443880 · $0.1332
Ran-Citalo · DIN 02285622 · $0.1332
Riva-Citalopram · DIN 02303264 · $0.1332
Sandoz Citalopram · DIN 02248170 · $0.1332
Septa-Citalopram · DIN 02355272 · $0.1332
Teva-Citalopram · DIN 02293218 · $0.1332
Shortage status: resolved shortage (ended 2017-12-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02248010
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Riva-Citalopram · DIN 02303264 · 20mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Riva-Citalopram · DIN 02303264
Manufacturer: Laboratoire Riva Inc.; listing date 2021-08-31
Health Canada: Marketed since 2008-01-28 · brand RIVA-CITALOPRAM · ATC N06AB04 CITALOPRAM · form Tablet · route Oral · ingredients CITALOPRAM (CITALOPRAM HYDROBROMIDE) 20 MG · company Laboratoire riva inc. · schedule Prescription
Riva-Citalopram: Formulary list price $0.1332/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1332 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78859 · Verify on the e-Formulary ↗ (DIN 02303264)
Source record
DIN 02303264: Riva-Citalopram
Raw flags: sec3=Y
Item: 281604096; group id 454; item number 1133; lccId None; manufacturer id RIA
Source form: Tab; strength: 20mg
Recorded listing: General benefit
Source prices (unrounded): $0.1332; ministry $0.1332
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02303264
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78859
Interchangeable products
Accel Citalopram Tablets · DIN 02355256 · $0.1332
Apo-Citalopram · DIN 02246056 · $0.1332
Auro-Citalopram · DIN 02275562 · $0.1332
CCP-Citalopram · DIN 02459914 · $0.1332
Celexa · DIN 02239607 · $0.1332
Citalopram · DIN 02353660 · $0.1332
Citalopram · DIN 02387956 · $0.1332
Citalopram · DIN 02430541 · $0.1332
Co Citalopram · DIN 02248050 · $0.1332
Jamp-Citalopram · DIN 02313405 · $0.1332
M-Citalopram · DIN 02467836 · $0.1332
Mar-Citalopram · DIN 02371898 · $0.1332
Mint-Citalopram · DIN 02429705 · $0.1332
NRA-Citalopram · DIN 02477645 · $0.1332
Natco-Citalopram · DIN 02443880 · $0.1332
PMS-Citalopram · DIN 02248010 · $0.1332
Ran-Citalo · DIN 02285622 · $0.1332
Sandoz Citalopram · DIN 02248170 · $0.1332
Septa-Citalopram · DIN 02355272 · $0.1332
Teva-Citalopram · DIN 02293218 · $0.1332
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02303264
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Teva-Citalopram · DIN 02293218 · 20mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Teva-Citalopram · DIN 02293218
Manufacturer: Teva Canada Limited; listing date 2007-11-10
Health Canada: Marketed since 2010-11-03 · brand TEVA-CITALOPRAM · ATC N06AB04 CITALOPRAM · form Tablet · route Oral · ingredients CITALOPRAM (CITALOPRAM HYDROBROMIDE) 20 MG · company Teva canada limited · schedule Prescription
Teva-Citalopram: Formulary list price $0.1332/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1332 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77858 · Verify on the e-Formulary ↗ (DIN 02293218)
Source record
DIN 02293218: Teva-Citalopram
Raw flags: sec3=Y
Item: 281604096; group id 454; item number 1133; lccId None; manufacturer id TEV
Source form: Tab; strength: 20mg
Recorded listing: General benefit
Source prices (unrounded): $0.1332; ministry $0.1332
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02293218
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77858
Interchangeable products
Accel Citalopram Tablets · DIN 02355256 · $0.1332
Apo-Citalopram · DIN 02246056 · $0.1332
Auro-Citalopram · DIN 02275562 · $0.1332
CCP-Citalopram · DIN 02459914 · $0.1332
Celexa · DIN 02239607 · $0.1332
Citalopram · DIN 02353660 · $0.1332
Citalopram · DIN 02387956 · $0.1332
Citalopram · DIN 02430541 · $0.1332
Co Citalopram · DIN 02248050 · $0.1332
Jamp-Citalopram · DIN 02313405 · $0.1332
M-Citalopram · DIN 02467836 · $0.1332
Mar-Citalopram · DIN 02371898 · $0.1332
Mint-Citalopram · DIN 02429705 · $0.1332
NRA-Citalopram · DIN 02477645 · $0.1332
Natco-Citalopram · DIN 02443880 · $0.1332
PMS-Citalopram · DIN 02248010 · $0.1332
Ran-Citalo · DIN 02285622 · $0.1332
Riva-Citalopram · DIN 02303264 · $0.1332
Sandoz Citalopram · DIN 02248170 · $0.1332
Septa-Citalopram · DIN 02355272 · $0.1332
Shortage status: resolved shortage (ended 2025-04-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02293218
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Citalopram · DIN 02246057 · 40mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Citalopram · DIN 02246057
Manufacturer: Apotex Inc.; listing date 2004-07-20
Health Canada: Marketed since 2004-01-21 · brand APO-CITALOPRAM · ATC N06AB04 CITALOPRAM · form Tablet · route Oral · ingredients CITALOPRAM (CITALOPRAM HYDROBROMIDE) 40 MG · company Apotex inc · schedule Prescription
Apo-Citalopram: Formulary list price $0.1332/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1332 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=70188 · Verify on the e-Formulary ↗ (DIN 02246057)
Source record
DIN 02246057: Apo-Citalopram
Raw flags: sec3=Y
Item: 281604097; group id 454; item number 1134; lccId None; manufacturer id APX
Source form: Tab; strength: 40mg
Recorded listing: General benefit
Source prices (unrounded): $0.1332; ministry $0.1332
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02246057
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=70188
Interchangeable products
Accel Citalopram Tablets · DIN 02355264 · $0.1332
Auro-Citalopram · DIN 02275570 · $0.1332
CCP-Citalopram · DIN 02459922 · $0.1332
Celexa · DIN 02239608 · $0.1332
Citalopram · DIN 02353679 · $0.1332
Citalopram · DIN 02387964 · $0.1332
Citalopram · DIN 02430568 · $0.1332
Co Citalopram · DIN 02248051 · $0.1332
Jamp-Citalopram · DIN 02313413 · $0.1332
M-Citalopram · DIN 02467844 · $0.1332
Mar-Citalopram · DIN 02371901 · $0.1332
Mint-Citalopram · DIN 02429713 · $0.1332
NRA-Citalopram · DIN 02477653 · $0.1332
Natco-Citalopram · DIN 02443899 · $0.1332
PMS-Citalopram · DIN 02248011 · $0.1332
Ran-Citalo · DIN 02285630 · $0.1332
Riva-Citalopram · DIN 02303272 · $0.1332
Sandoz Citalopram · DIN 02248171 · $0.1332
Septa-Citalopram · DIN 02355280 · $0.1332
Teva-Citalopram · DIN 02293226 · $0.1332
Shortage status: shortage reported ended 2026-06-05 (report last updated 2026-06-05); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02246057
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Citalopram · DIN 02387948 · 10mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Citalopram · DIN 02387948
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2025-02-28
Health Canada: Marketed since 2024-02-27 · brand CITALOPRAM · ATC N06AB04 CITALOPRAM · form Tablet · route Oral · ingredients CITALOPRAM (CITALOPRAM HYDROBROMIDE) 10 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87351 · Verify on the e-Formulary ↗ (DIN 02387948)
Source record
DIN 02387948: Citalopram
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 281604143; group id 454; item number 1132; lccId None; manufacturer id SIV
Source form: Tab; strength: 10mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.4464; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02387948
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87351
Interchangeable products
Celexa · DIN 02239606 · not recorded
Citalopram · DIN 02430517 · not recorded
Citalopram · DIN 02445719 · not recorded
Jamp-Citalopram · DIN 02370085 · not recorded
M-Citalopram · DIN 02532123 · not recorded
Mar-Citalopram · DIN 02371871 · not recorded
Natco-Citalopram · DIN 02409003 · not recorded
PMS-Citalopram · DIN 02270609 · not recorded
Shortage status: resolved shortage (ended 2021-12-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02387948
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Citalopram · DIN 02430517 · 10mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Citalopram · DIN 02430517
Manufacturer: Jamp Pharma Corporation; listing date 2024-12-30
Health Canada: Marketed since 2020-03-06 · brand CITALOPRAM · ATC N06AB04 CITALOPRAM · form Tablet · route Oral · ingredients CITALOPRAM (CITALOPRAM HYDROBROMIDE) 10 MG · company Jamp pharma corporation · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91495 · Verify on the e-Formulary ↗ (DIN 02430517)
Source record
DIN 02430517: Citalopram
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 281604143; group id 454; item number 1132; lccId None; manufacturer id JPC
Source form: Tab; strength: 10mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.4464; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02430517
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91495
Interchangeable products
Celexa · DIN 02239606 · not recorded
Citalopram · DIN 02387948 · not recorded
Citalopram · DIN 02445719 · not recorded
Jamp-Citalopram · DIN 02370085 · not recorded
M-Citalopram · DIN 02532123 · not recorded
Mar-Citalopram · DIN 02371871 · not recorded
Natco-Citalopram · DIN 02409003 · not recorded
PMS-Citalopram · DIN 02270609 · not recorded
Shortage status: resolved shortage (ended 2024-09-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02430517
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Citalopram · DIN 02445719 · 10mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Citalopram · DIN 02445719
Manufacturer: Sanis Health Inc.; listing date 2026-01-30
Health Canada: Marketed since 2015-10-14 · brand CITALOPRAM · ATC N06AB04 CITALOPRAM · form Tablet · route Oral · ingredients CITALOPRAM (CITALOPRAM HYDROBROMIDE) 10 MG · company Sanis health inc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93099 · Verify on the e-Formulary ↗ (DIN 02445719)
Source record
DIN 02445719: Citalopram
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 281604143; group id 454; item number 1132; lccId None; manufacturer id SAI
Source form: Tab; strength: 10mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.4464; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02445719
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93099
Interchangeable products
Celexa · DIN 02239606 · not recorded
Citalopram · DIN 02387948 · not recorded
Citalopram · DIN 02430517 · not recorded
Jamp-Citalopram · DIN 02370085 · not recorded
M-Citalopram · DIN 02532123 · not recorded
Mar-Citalopram · DIN 02371871 · not recorded
Natco-Citalopram · DIN 02409003 · not recorded
PMS-Citalopram · DIN 02270609 · not recorded
Shortage status: resolved shortage (ended 2018-01-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02445719
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp-Citalopram · DIN 02370085 · 10mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jamp-Citalopram · DIN 02370085
Manufacturer: Jamp Pharma Corporation; listing date 2026-06-30
Health Canada: Marketed since 2025-09-12 · brand JAMP-CITALOPRAM · ATC N06AB04 CITALOPRAM · form Tablet · route Oral · ingredients CITALOPRAM (CITALOPRAM HYDROBROMIDE) 10 MG · company Jamp pharma corporation · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85511 · Verify on the e-Formulary ↗ (DIN 02370085)
Source record
DIN 02370085: Jamp-Citalopram
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 281604143; group id 454; item number 1132; lccId None; manufacturer id JPC
Source form: Tab; strength: 10mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.4464; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02370085
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85511
Interchangeable products
Celexa · DIN 02239606 · not recorded
Citalopram · DIN 02387948 · not recorded
Citalopram · DIN 02430517 · not recorded
Citalopram · DIN 02445719 · not recorded
M-Citalopram · DIN 02532123 · not recorded
Mar-Citalopram · DIN 02371871 · not recorded
Natco-Citalopram · DIN 02409003 · not recorded
PMS-Citalopram · DIN 02270609 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02370085
Shortage record checked 2026-09-13T08:10:21.292534+00:00
M-Citalopram · DIN 02532123 · 10mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
M-Citalopram · DIN 02532123
Manufacturer: Mantra Pharma Inc.; listing date 2025-05-30
Health Canada: Marketed since 2023-11-13 · brand M-CITALOPRAM · ATC N06AB04 CITALOPRAM · form Tablet · route Oral · ingredients CITALOPRAM (CITALOPRAM HYDROBROMIDE) 10 MG · company Mantra pharma inc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102119 · Verify on the e-Formulary ↗ (DIN 02532123)
Source record
DIN 02532123: M-Citalopram
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 281604143; group id 454; item number 1132; lccId None; manufacturer id MAT
Source form: Tab; strength: 10mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.4464; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02532123
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102119
Interchangeable products
Celexa · DIN 02239606 · not recorded
Citalopram · DIN 02387948 · not recorded
Citalopram · DIN 02430517 · not recorded
Citalopram · DIN 02445719 · not recorded
Jamp-Citalopram · DIN 02370085 · not recorded
Mar-Citalopram · DIN 02371871 · not recorded
Natco-Citalopram · DIN 02409003 · not recorded
PMS-Citalopram · DIN 02270609 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02532123
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mar-Citalopram · DIN 02371871 · 10mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mar-Citalopram · DIN 02371871
Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2025-03-31
Health Canada: Marketed since 2012-09-06 · brand MAR-CITALOPRAM · ATC N06AB04 CITALOPRAM · form Tablet · route Oral · ingredients CITALOPRAM (CITALOPRAM HYDROBROMIDE) 10 MG · company Marcan pharmaceuticals inc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85700 · Verify on the e-Formulary ↗ (DIN 02371871)
Source record
DIN 02371871: Mar-Citalopram
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 281604143; group id 454; item number 1132; lccId None; manufacturer id MAR
Source form: Tab; strength: 10mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.4464; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02371871
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85700
Interchangeable products
Celexa · DIN 02239606 · not recorded
Citalopram · DIN 02387948 · not recorded
Citalopram · DIN 02430517 · not recorded
Citalopram · DIN 02445719 · not recorded
Jamp-Citalopram · DIN 02370085 · not recorded
M-Citalopram · DIN 02532123 · not recorded
Natco-Citalopram · DIN 02409003 · not recorded
PMS-Citalopram · DIN 02270609 · not recorded
Shortage status: resolved shortage (ended 2021-07-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02371871
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Natco-Citalopram · DIN 02409003 · 10mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Natco-Citalopram · DIN 02409003
Manufacturer: Natco Pharma (Canada) Inc.; listing date 2024-12-30
Health Canada: Marketed since 2023-09-08 · brand NATCO-CITALOPRAM · ATC N06AB04 CITALOPRAM · form Tablet · route Oral · ingredients CITALOPRAM (CITALOPRAM HYDROBROMIDE) 10 MG · company Natco pharma (canada) inc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89374 · Verify on the e-Formulary ↗ (DIN 02409003)
Source record
DIN 02409003: Natco-Citalopram
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 281604143; group id 454; item number 1132; lccId None; manufacturer id NAT
Source form: Tab; strength: 10mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.4464; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02409003
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89374
Interchangeable products
Celexa · DIN 02239606 · not recorded
Citalopram · DIN 02387948 · not recorded
Citalopram · DIN 02430517 · not recorded
Citalopram · DIN 02445719 · not recorded
Jamp-Citalopram · DIN 02370085 · not recorded
M-Citalopram · DIN 02532123 · not recorded
Mar-Citalopram · DIN 02371871 · not recorded
PMS-Citalopram · DIN 02270609 · not recorded
Shortage status: resolved shortage (ended 2024-11-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02409003
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PMS-Citalopram · DIN 02270609 · 10mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PMS-Citalopram · DIN 02270609
Manufacturer: Pharmascience Inc.; listing date 2025-02-28
Health Canada: Marketed since 2005-09-10 · brand PMS-CITALOPRAM · ATC N06AB04 CITALOPRAM · form Tablet · route Oral · ingredients CITALOPRAM (CITALOPRAM HYDROBROMIDE) 10 MG · company Pharmascience inc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75597 · Verify on the e-Formulary ↗ (DIN 02270609)
Source record
DIN 02270609: PMS-Citalopram
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 281604143; group id 454; item number 1132; lccId None; manufacturer id PMS
Source form: Tab; strength: 10mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.4464; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02270609
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75597
Interchangeable products
Celexa · DIN 02239606 · not recorded
Citalopram · DIN 02387948 · not recorded
Citalopram · DIN 02430517 · not recorded
Citalopram · DIN 02445719 · not recorded
Jamp-Citalopram · DIN 02370085 · not recorded
M-Citalopram · DIN 02532123 · not recorded
Mar-Citalopram · DIN 02371871 · not recorded
Natco-Citalopram · DIN 02409003 · not recorded
Shortage status: resolved shortage (ended 2018-05-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02270609
Shortage record checked 2026-09-13T08:10:21.292534+00:00